Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VR102
- Development stage
- Phase 2
- Lead developer
- VaRi Bioscience
- Modality
- Small Molecules
- Administration
- Vaginal
01
Overview
VR102 is a first-in-class, long-acting vaginal ring developed by VaRi Bioscience for the treatment of vulvovaginal atrophy (VVA). It functions as a local estrogen therapy, delivering estrogen directly to the vaginal tissues to alleviate symptoms such as dryness, itching, and dyspareunia associated with menopause-induced estrogen deficiency. The ring is designed for sustained release, providing a long-acting therapeutic effect that aims to improve patient compliance and efficacy compared to existing short-acting local treatments. The program has completed initial development activities and is currently in Phase 2 clinical development.
- Other names
- estriol vaginal ring
02
Targets
ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on VR102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VR102.